Maria Amann

1.3k total citations
19 papers, 384 citations indexed

About

Maria Amann is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Maria Amann has authored 19 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Immunology. Recurrent topics in Maria Amann's work include Monoclonal and Polyclonal Antibodies Research (11 papers), CAR-T cell therapy research (9 papers) and Immune Cell Function and Interaction (6 papers). Maria Amann is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), CAR-T cell therapy research (9 papers) and Immune Cell Function and Interaction (6 papers). Maria Amann collaborates with scholars based in Switzerland, United States and Germany. Maria Amann's co-authors include Patrick A. Baeuerle, Petra Lutterbuese, Peter Kufer, Bernd Schlereth, Grit Lorenczewski, Roman Kischel, Klaus Brischwein, Ralf Lutterbuese, Stacy Fuhrmann and Steve Coats and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Maria Amann

19 papers receiving 369 citations

Peers

Maria Amann
Noriko Maeda Japan
Shinichiro Izawa Japan
Margreet Lang Netherlands
Xianjing Chu China
Asona Lui United States
De Sen Wan China
Marta Escorihuela Spain
Yaqun Li China
Mao Zhang China
Apostolos Menegakis Germany
Noriko Maeda Japan
Maria Amann
Citations per year, relative to Maria Amann Maria Amann (= 1×) peers Noriko Maeda

Countries citing papers authored by Maria Amann

Since Specialization
Citations

This map shows the geographic impact of Maria Amann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Amann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Amann more than expected).

Fields of papers citing papers by Maria Amann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Amann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Amann. The network helps show where Maria Amann may publish in the future.

Co-authorship network of co-authors of Maria Amann

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Amann. A scholar is included among the top collaborators of Maria Amann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Amann. Maria Amann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Gadwa, Jacob, Justin Yu, Miles Piper, et al.. (2025). Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 13(1). e010405–e010405. 1 indexed citations
2.
Pascual, Marién, Enrique Goñi, Marı́a A. Burrell, et al.. (2025). IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy. Blood. 145(23). 2746–2761. 6 indexed citations
3.
Varypataki, Eleni Maria, Simone Lang, Marine Richard, et al.. (2025). Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies. OncoImmunology. 14(1). 2526444–2526444. 2 indexed citations
4.
Belli, Sara, Maria Amann, Lucy Hutchinson, et al.. (2024). Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody. Clinical Pharmacology & Therapeutics. 116(3). 834–846. 3 indexed citations
5.
Gadwa, Jacob, Maria Amann, Thomas E. Bickett, et al.. (2023). Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell Reports Medicine. 4(8). 101150–101150. 14 indexed citations
6.
Korfi, Koorosh, Bruno C. Medeiros, Marco Berrera, et al.. (2023). CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia. Frontiers in Oncology. 13. 1150149–1150149. 6 indexed citations
7.
Darragh, Laurel B., Jacob Gadwa, Tiffany Pham, et al.. (2022). Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nature Communications. 13(1). 7015–7015. 94 indexed citations
8.
Ceppi, Maurizio, Michael Hettich, Volker Teichgräber, et al.. (2020). Abstract 6135: Tumor-bearing non-human primates: An unrivaled model for translational cancer immunology research. Cancer Research. 80(16_Supplement). 6135–6135. 4 indexed citations
9.
Claus, Christina, Claudia Ferrara, Sabine M. Lang, et al.. (2017). Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells. Cancer Research. 77(13_Supplement). 3634–3634. 4 indexed citations
10.
11.
Friedrich, Matthias, et al.. (2010). Abstract 2433: Eradication of established pancreatic tumors in mice by engagement of extra-tumoral human T cells with BiTE antibody MT110. Cancer Research. 70(8_Supplement). 2433–2433. 1 indexed citations
12.
Fuhrmann, Stacy, Maria Amann, Kathy Mulgrew, et al.. (2010). Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas. Cancer Research. 70(8_Supplement). 5625–5625. 1 indexed citations
13.
Peng, Li, Michael D. Oberst, Jiaqi Huang, et al.. (2010). Abstract 2584: The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope present in the full-length but not a short splice variant of CEA. Cancer Research. 70(8_Supplement). 2584–2584. 3 indexed citations
14.
Amann, Maria, Grit Lorenczewski, Klaus Brischwein, et al.. (2009). Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release. Journal of Immunotherapy. 32(5). 452–464. 43 indexed citations
15.
Amann, Maria, Matthias Friedrich, Petra Lutterbuese, et al.. (2008). Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunology Immunotherapy. 58(1). 95–109. 30 indexed citations
16.
Amann, Maria, Klaus Brischwein, Petra Lutterbuese, et al.. (2008). Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3. Cancer Research. 68(1). 143–151. 68 indexed citations
17.
Lutterbuese, Ralf, et al.. (2008). Conversion of Cetuximab and Trastuzumab into T cell-engaging BiTE antibodies creates novel drug candidates with superior anti-tumor activity. 68. 2402–2402. 3 indexed citations
18.
Baeuerle, Patrick A., Maria Amann, Klaus Brischwein, et al.. (2007). Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3. Molecular Cancer Therapeutics. 6. 3 indexed citations
19.
Rodrigues, A. David, J L Ferrero, Maria Amann, et al.. (1994). The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.. Drug Metabolism and Disposition. 22(5). 788–798. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noriko Maeda Breakdown of academic impact, for papers by Shinichiro Izawa Breakdown of academic impact, for papers by Margreet Lang Breakdown of academic impact, for papers by Xianjing Chu Breakdown of academic impact, for papers by Asona Lui Breakdown of academic impact, for papers by De Sen Wan Breakdown of academic impact, for papers by Marta Escorihuela Breakdown of academic impact, for papers by Yaqun Li Breakdown of academic impact, for papers by Mao Zhang Breakdown of academic impact, for papers by Apostolos Menegakis
Rankless by CCL
2026